Evaluation of tissue expression and salivary levels of HER2/neu in patients with head and neck squamous cell carcinoma

Iranian Journal of Otorhinolaryngology

Volumn 24, Issue 69, 2012, Pages 161-170

  Pardis, Soheil ^a   Sardari, Yasaman ^a   Ashraf, Mohammad Javad ^b   Tadbir, Azadeh Andisheh ^a   Ebrahimi, Hooman ^a   Purshahidi, Sara ^c   Khademi, Bijan ^c   Fattahi, Mohammad Javad ^d   Hamzavi, Marzieh ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carcinoma; HER2 neu; Salivary gland; Squamous cell of head and neck; Tissue expression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SALIVA ANALYSIS; TUMOR CELL; TUMOR VOLUME;

EID: 84874185435     PISSN: 22517251     EISSN: 2251726X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity.CA Cancer J Clin 2005; 55(4):242-58
2. Anthony SF, Euqene B, Dennis LK, Stephen LH, Dan LL, Larry J et al. Harrison's principles of internal medicine. 17th ed. McGraw-Hill; 2008:548-51.
3. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86(6):347-63.
4. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptorfamily and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785(2): 232-65.
5. Albuquerque RL Jr, Miguel MC, Costa AL, Souza LB. Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma. Int J Exp Pathol 2003; 84(6):259-65.
6. Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol 2004; 40(7):688-96.
7. Seifi S, Shafaei SN, Nosrati K, Ariaeifar B. Lack of elevated HER2/neu expression in epithelial dysplasia and oral squamous cell carcinoma in Iran. Asian Pac J Cancer Prev 2009; 10(4):661-4.
8. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7(Suppl 4): 31-9.
9. Salem M, Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M et al. Association between the HER2expression and histologicaldifferentiation in Wilms tumor. Pediatr Surg Int 2006; 22(11):891-6.
10. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82(2-3): 241-50.
11. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-70.
12. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22(1): 77-85.
13. Crombet T, Osorio M, Cruz T, Roca C, Castillo R d, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22(9):1646-54.
14. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G.Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007; 29(7):655-64.
15. Xia W, Lau YK, Zhang HZ, Xiao FY, Johston DA, Liu AR, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5:4164-74.
16. Shiga H, Rasmussen AA, Johnston PG, Langmacher M, Baylor A, Lee M, et al. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck 2000; 22(6): 599-608.
17. Werkmeister R, Brandt B, Joos U. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 2000; 36(1):100-5.
18. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005; 11: 397-405.
19. Bernardes V, Gleber-Netto F, Sousa S, Silva T, Aguiar M. Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. J Exp Clin Cancer Res 2010; 29(1): 40.
20. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61(17):6500-10.
21. Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y. Immunohistochemicalstudy of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 1992; 102(8): 923-7.
22. Schechler AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229(4717): 976-78.
23. Kearsley JH, Leonard JH, Walsh MD, Wright G. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 1991; 23(3):189-94.
24. Reviere A, Becker J, Loning T. Comparative investigation of c-erbB-2/neu expression in head and neck tumors and mammary cancer. Cancer 1991; 67(8): 2142-9.
25. Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992; 12:2273-6.
26. Field JK, Spandidos DA, Yiagnisis M, Gosney JR, Papadimitriou K, Stell PM. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Responsibility 1992; 12(3): 613-19.
27. Ekberg T, Nestor M, Engström M, Nordgren H, Wester K, Carlsson J et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 2005; 26(5):1177-85.
28. Angiero F, Sordo RD, Dessy E, Rossi E, Berenzi A, Stefani M et al. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters? J Oral Pathol Med 2008; 37(3):145-50.
29. Mort Tefler MR, Shepherd JP. Psychological distress in patients attending an oncology clinic after definitive treatment for maxillofacial malignant neoplasia. Int J Oral Maxillofac Surg 1993; 22: 347-9.
30. Lebeau A, Delming D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, et al. HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization. J Clin Oncol 2001; 19(2): 354-63.
31. Fong Y, Chou SJ, Hung KF, Wu HT, Kao SYJ. An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. Chin Med Assoc 2008; 71(3):123-7.
32. Wilkman TS, Hietanen JH, Malmström MJ, Konttinen YT. Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg 1998; 27: 209-12.
33. Rautava J, Jee KJ, Miettinen PJ, Nagy B, Myllykangas S, Odell EW et al. ERBB receptors in developing, dysplastic and malignant oral epithelia. Oral Oncol 2008; 44(3): 227-35.
34. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res1997; 3(1):3-9.
35. Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H. Interobserver reproducibility of HER-2/neu protein overexpression in invasive breast carcinoma using DAKO HercepTest. Am J Clin Pathol 2002; 118: 693-8.
36. Quon, H, Liu, FF,Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23(2): 147-59.
37. Tse GM, Yu KH, Chan AW, King AD, Chen GG, Wong KT et al. HER2 expression predicts improved survival in patients with cervical node-positive head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 141(4):467-73.
38. Streckfus CF, Bigler LR. Saliva as a diagnostic fluid. Oral Dis 2002; 8:69-76.
39. Lawrence HP. Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 2002; 68(3):170-4.